A number of new approaches to cancer have emerged recently. They include immunotherapy, in which the tumour cells are eliminated by the body’s own immune defence; starving the tumour by inhibiting capillary growth; and correcting known defects in the tumour cells with highly specific, targeted drugs that stop their unregulated growth.
Other routes to improving cancer therapies involve probing the cellular DNA to understand why some cells divide “wrongly” and become tumours. Is it possible to check or influence tumour growth in these cells, which are genetically programmed to develop cancer?
Some new therapeutic methods are already in clinical use alongside the conventional surgery, radiotherapy and chemotherapy; others are still at the basic research stage.
Attending the two-day conference will be two dozen of the worlds foremost cancer researchers, who will be talking about the latest results in their particular fields. Several programme items will be dealing with malignant melanoma.
Journalists are invited to “Frontiers in Cancer Research and Therapy” to attend the lectures and interview the researchers involved.
Date: Thursday 8 and Friday 9 March
Venue: Nobel Forum, Nobels väg 1, Karolinska Institutet Solna campus.
Sample programme items:
•Genomics. The DNA of tumours can be sequenced using powerful new methods. Which genes are mutated in different tumours, and what clinical significance can this have?
•Cancer vaccination. New ways of inducing a patients own immune defence to attack a tumour.
•Heterogeneity. How can we attack tumours comprising many different kinds of cell with different mutations in DNA?
Arrangers: Klas Wiman, Andreas Lundqvist, Ola Larsson, Thierry Soussi and Johan Hansson from the Department of Oncology-Pathology, Karolinska Institutet.
For further information, contact:
Professor Klas Wiman
Office: +46(0)8-517 793 42
Mobile: +46(0)73-986 65 86
E-mail:klas.wiman@ki.se
Press Officer Sabina Bossi
Office: +46(0)8-524 860 66
Mobile: +46(0)70- 614 60 66
E-mail:sabina.bossi@ki.se
Karolinska Institutet is one of the world’s leading medical universities. It accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.
28 February, 2023 - Karolinska Institutet
Following a successful pilot study, an online anonymous treatment program aimed at reducing child sexual abuse by providing treatment to individuals who exhibit sexual urges towards children is being launched across the EU. It is now available in Swedish, German, and Portuguese as well as in an updated English version. The treatment program, which has […]
29 April, 2021 - Karolinska Institutet
Researchers at Karolinska Institutet and the Public Health Agency of Sweden have studied newborn babies whose mothers tested positive for SARS-CoV-2 during pregnancy or childbirth. The results show that although babies born of test-positive mothers are more likely to be born early, extremely few were infected with COVID-19. The study, which is published in the […]
27 April, 2020 - Karolinska Institutet
Only about five per cent of the babies born to mothers with hepatitis C are themselves infected by the disease. A possible reason for this low figure is that the baby’s immune system has already destroyed the virus before birth. A new study from researchers at KI and published in the journal Gut reveals clear […]
7 April, 2020 - Karolinska Institutet
People with celiac disease have increased risk of dying prematurely, despite increased awareness of the disease in recent years and better access to gluten-free food. This is according to a new study from Karolinska Institutet in Sweden and Columbia University in the U.S. published in the prestigious journal JAMA. Celiac disease was linked to increased […]
Expertsvar, The Swedish Research Council, Hantverkargatan 11B, Stockholm SWEDENPhone +46(0)8 546 44 000
P.O. Box 1035, SE-101 38 Stockholm, expertsvar@vr.se
Information about cookies will open in a new window
